


Figure 1


Light gray = chain A
Dark gray = chain B
Black = selected sites



6RLX
Insulin numbering
Site not in structure: A Q-3

Figure 2


Light gray = chain A
Dark gray = chain B
Black = selected sites



6RLX
Insulin numbering
Site not in structure: A Q-3

Figure 3

Light blue= chain A
Dark blue= chain B
Yellow = receptor binding site
Orange= selected sites



6RLX
Insulin numbering
Site not in structure: A Q-3

Figure 4




Figure 5





Figure 6

A.


SDS-PAGE → unPEGylated Relaxin



Lane #	Lane assignment
1	MW Marker
2	---
3	wt Relaxin (NR)
4	---
5	MW Marker
6	---
7	wt Relaxin (R)

B.

SDS-PAGE → 20K PEGylated Relaxin



Lane #	Lane assignment
1	MW Marker
2	---
3	20K PEG Relaxin (NR)
4	20K PEG Relaxin (R)

Figure 7




Figure 8A




Figure 8B

Individual PEG20-AQ1-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 9A

Individual PEG20-AA5-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 9B

Individual PEG20-AR18-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 10A

Individual PEG20-BV7-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 10B

Individual PEG20-BW28-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 11

Individual PEG20-AV13-RLX serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 12A

Mean RLX serum concentration versus time
Error bars=Std Dev, Gender=males
Dose=0.5mg/kg, Route = SC




Figure 12B

Individual wt rhRelaxin serum concentration versus time
Gender=males
Dose=0.5mg/kg, Route = SC




Figure 13A




Figure 13B




Figure 14A




Figure 14B




Figure 15




Figure 16A




Figure 16B




Figure 17A




Figure 17B




Figure 18A




Figure 18B




Figure 19, Part A




Figure 19, Part B




Figure 19, Part C




Figure 19, Part D




Figure 19, Part E




Figure 19, Part F




Figure 20, Part A




Figure 20, Part B




Figure 20, Part C




Figure 20, Part D




Figure 20, Part E




Figure 20, Part F




Figure 20, Part G

**Effect of PEG-Relaxin Variant IV Administration on
Water Intake(0-6hr) in Female Long-Evans Rats**




Figure 20, Part H

**Baseline Urine Output (-16-0hr)
in Female Long-Evans Rats**




Figure 20, Part I

**Effect of PEG-Relaxin Variant IV Administration
on Urine Output (0-6hr) in Female Long-Evans Rats**

